Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Momelotinib in VEXAS Syndrome With or Without MDS
NCT07098936Phase 2Recruiting
- Sponsor
- Groupe Français des Myélodysplasies
- Start
- Nov 2025
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mivavotinib in VEXAS syndrome (VEXAS), myelodysplastic syndrome (MDS), sponsored by Groupe Français des Myélodysplasies. Started Nov 2025; status: recruiting.
02
Drugs
mivavotinib
03
Conditions
VEXAS syndrome (VEXAS)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT07098936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07098936.